Test maker’s shares soar on GSK cancer pact

Shares of diagnostic test maker Response Genetics (RGDX) spiked 51 percent on the news that pharma powerhouse GlaxoSmithKline had inked a non-exclusive deal covering the rights to its technology to assess BRAF gene mutations in tumor samples. The BRAF gene encodes B-Raf proto-oncogene serine/threonine-protein kinase, a protein involved in cell signaling and cellular growth and differentiation. Specific genetic mutations have been correlated with the development of certain forms of cancer....